Neuralstem (CUR) Stock Price, News & Analysis

Company Overview

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Key Stats

• Today's Range: $1.49 to $1.62
• 50-Day Range: $0.67 to $1.52
• 52-Week Range: $1.10 to $13.78
• Volume: 215,185 shs
• Average Volume: 236,278 shs
• Market Capitalization: $3.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CUR Stock Analysis - Frequently Asked Questions

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.45) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative trailing twelve-month return on equity of 170.51%.

When did Neuralstem's stock split?

Shares of Neuralstem reverse split before market open on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Neuralstem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), SELLAS Life Sciences Group (SLS) and ACADIA Pharmaceuticals (ACAD).

Company Calendar

• Last Earnings: 8/14/2019
• Today: 1/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CUR
• CUSIP: N/A
• CIK: 1357459
• Web: www.neuralstem.com
• Phone: 301-366-4841
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,930,000.00
• Net Margins: -39,417.64%
• Pretax Margin: N/A
• Return on Equity: -170.51%
• Return on Assets: -110.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.53
• Quick Ratio: 2.53

Sales & Book Value

• Annual Sales: $260,000.00
• Price / Sales: 12.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.64 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 2,100,000
• Free Float: N/A
• Market Cap: $3.17 million
• Optionable: Not Optionable
• Beta: 1.81